laquinimod Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.   Wikipedia

Chemistry

  • SMILES: CCN(C(=O)C1=C(O)c2c(Cl)cccc2N(C)C1=O)c3ccccc3
  • InChIKey: GKWPCEFFIHSJOE-UHFFFAOYSA-N
  • Mol. Mass: 356.81
  • ALogP: 3.56
  • ChEMBL Molecules:
    laquinimod  
    laquinimod sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

abr215062 | abr 215062 | abr-215062 | abr-215062 sodium | laquinimod | laquinimod sodium | saik-ms | tv-5600

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Crohn Disease (Phase 2)

Eye Diseases (Phase 1)

Huntington Disease (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Pharmacokinetics (Phase 1)

Uveitis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue